Aby J.  Mathew net worth and biography

Aby Mathew Biography and Net Worth

Dr. Mathew was part of the founding team of BioLife Solutions, Inc., and is a co-developer of BioLife’s biopreservation media solutions. He is a co-inventor on multiple issued and pending patents related to methods, devices, and formulations for the preservation of cells, tissues, and organs. He holds a Ph.D. in Biological Sciences within the Biochemistry, Cell and Molecular Biology Program from Binghamton University and a B.S. in Microbiology from Cornell University. Dr. Mathew has been researching low temperature biopreservation since 1994, and his studies contributed to the development of BioLife’s current commercial HypoThermosol® and CryoStor® product platforms and intellectual property foundation. Dr. Mathew was part of the scientific team that linked cell death via apoptosis (programmed cell death) to exposure to hypothermic and/or freezing temperatures. These discoveries were integral to the development of BioLife’s intracellular-like biopreservation media, and also contributed to improvements in cryosurgical ablation of cancer. Dr. Mathew was BioLife’s first Director of Manufacturing, established BioLife’s initial Quality system, and has been Executive Vice President & Chief Scientific Officer since December 2019. From February 2011 through November 2019, Dr. Mathew served as Senior Vice President & Chief Technology Officer. From January 2007 through February 2011, Dr. Mathew served as Senior Scientist, Director of Strategic Relations, and Senior Director of Strategic Relations. From June 2003 through January 2007, Dr. Mathew served as Director of Manufacturing. From September 2000 through June 2003, Dr. Mathew served as Clinical Accounts Manager and Director of Hypothermic Preservation for Cryomedical Sciences/BioLife Solutions. Dr. Mathew is currently active in, or previously a member of, AABB (formerly the American Association of Blood Banks), BEST (the Biomedical Excellence for Safer Transfusion collaborative), the International Society for Cell and Gene Therapy (ISCT), the Alliance for Regenerative Medicine (ARM), Tissue Engineering & Regenerative Medicine International Society (TERMIS), Society for Cryobiology, International Society for Biological and Environmental Repositories (ISBER), American Society for Cell Biology, and the Society for In Vitro Biology. Dr. Mathew is a member of: the Board of Directors, and Advisory Panel, of the Parent’s Guide to Cord Blood Foundation, the Scientific Advisory Board of HemaCare Corporation, the founding Board of Directors of the Cord Blood Association, the NIST-AMTech National Cell Manufacturing Consortium, the California Institute for Regenerative Medicine (CIRM) Clinical Advisory Panel, the Business Advisory Board of RoosterBio Inc., and the Scientific Advisory Board of SAVSU Technologies. Dr. Mathew has obtained UCLA Corporate Governance Program Certification

What is Aby J. Mathew's net worth?

The estimated net worth of Aby J. Mathew is at least $7.00 million as of February 12th, 2025. Dr. Mathew owns 262,623 shares of BioLife Solutions stock worth more than $7,004,155 as of February 22nd. This net worth estimate does not reflect any other assets that Dr. Mathew may own. Additionally, Dr. Mathew receives a salary of $448,200.00 as VP at BioLife Solutions. Learn More about Aby J. Mathew's net worth.

How old is Aby J. Mathew?

Dr. Mathew is currently 52 years old. There are 6 older executives and no younger executives at BioLife Solutions. The oldest executive at BioLife Solutions is Mr. Roderick de Greef, CEO & Chairman, who is 64 years old. Learn More on Aby J. Mathew's age.

What is Aby J. Mathew's salary?

As the VP of BioLife Solutions, Inc., Dr. Mathew earns $448,200.00 per year. There are 2 executives that earn more than Dr. Mathew. The highest earning executive at BioLife Solutions is Mr. Roderick de Greef, CEO & Chairman, who commands a salary of $1,630,000.00 per year. Learn More on Aby J. Mathew's salary.

How do I contact Aby J. Mathew?

The corporate mailing address for Dr. Mathew and other BioLife Solutions executives is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. BioLife Solutions can also be reached via phone at (425) 402-1400 and via email at rdegreef@biolifesolutions.com. Learn More on Aby J. Mathew's contact information.

Has Aby J. Mathew been buying or selling shares of BioLife Solutions?

Over the course of the past ninety days, Aby J. Mathew has sold $13,357.76 in BioLife Solutions stock. Most recently, Aby J. Mathew sold 92 shares of the business's stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $26.54, for a transaction totalling $2,441.68. Following the completion of the sale, the executive vice president now directly owns 262,623 shares of the company's stock, valued at $6,970,014.42. Learn More on Aby J. Mathew's trading history.

Who are BioLife Solutions' active insiders?

BioLife Solutions' insider roster includes Sarah Aebersold (VP), Todd Berard (CMO), Roderick de Greef (CFO), Karen Foster (Insider), Andrew Hinson (Director), Aby Mathew (VP), Michael Rice (CEO), Joseph Schick (Director), Marcus Schulz (CRO), and Troy Wichterman (CFO). Learn More on BioLife Solutions' active insiders.

Are insiders buying or selling shares of BioLife Solutions?

In the last twelve months, insiders at the medical equipment provider sold shares 68 times. They sold a total of 179,217 shares worth more than $3,860,661.93. The most recent insider tranaction occured on February, 12th when EVP Aby J Mathew sold 92 shares worth more than $2,441.68. Insiders at BioLife Solutions own 2.2% of the company. Learn More about insider trades at BioLife Solutions.

Information on this page was last updated on 2/12/2025.

Aby J. Mathew Insider Trading History at BioLife Solutions

Aby J. Mathew Buying and Selling Activity at BioLife Solutions

This chart shows Aby J Mathew's buying and selling at BioLife Solutions by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$13ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

BioLife Solutions Company Overview

BioLife Solutions logo
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $26.67
Low: $26.42
High: $27.90

50 Day Range

MA: $26.93
Low: $24.98
High: $28.49

2 Week Range

Now: $26.67
Low: $14.50
High: $29.55

Volume

259,865 shs

Average Volume

238,085 shs

Market Capitalization

$1.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91